SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

OpenAI

OpenAI is receiving significant attention as it progresses toward a confidential IPO, with recent reports indicating a possible listing for a massive valuation. The conversation also focuses on the company's competitive landscape, including its rivalry with Anthropic and recent management changes.

Anthropic

The community conversation is dominated by discussions surrounding the highly anticipated IPO of Anthropic, with many traders debating its valuation and competitive positioning against OpenAI. Sentiment is divided between skepticism regarding extreme growth projections and enthusiasm for its enterprise adoption, though some participants remain focused on potential risks from regulatory scrutiny and internal governance shifts.

the cat on Base  community-run home for $BASECAT

Basecat

Basecat is experiencing significant volatility and trading volume as traders speculate on its potential as a new meme coin following its recent exchange listing. While some investors are actively buying the dip in anticipation of a price reversal, others express skepticism, describing the current price action as a pump-and-dump scenario.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing intense debate as some traders speculate on long-term institutional adoption driven by the project's infrastructure development and acquisition of Chain technology, while vocal skeptics label the project a long-standing pump-and-dump scheme due to stagnant price action and lack of confirmed partnerships. Community discussion is characterized by a stark divide between long-term holders accumulating in anticipation of a breakthrough and traders warning of continued dilution and poor performance.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

The community conversation remains fragmented, with traders debating whether to accumulate tokens in anticipation of potential future gains from the Clarity Act or to divest due to frustration over stagnant price action and previous losses. While some investors interpret the current price levels as a long-term buying opportunity for utility-focused assets, others express significant skepticism, labeling the project a scam and highlighting concerns about token dilution.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The SPDR S&P Biotech ETF is experiencing a bullish trend, with community discussion centered on technical breakouts and optimism regarding sector-wide M&A activity and late-stage clinical readouts. While some traders are expressing caution about potential consolidation or overbought conditions following recent gains, the broader sentiment remains focused on the sector's recovery and the high strategic value of pipeline assets.

Grayscale Ethereum Trust (ETH) operates as open-end investment company. Its investment objective is for the shares to reflect the value of ETH held by the trust. The company was founded on December 13, 2017 and is headquartered in Stamford, CT.

Grayscale Ethereum Staking Mini ETF - Common units of fractional undivided beneficial interest

Grayscale Ethereum Mini Trust

The conversation surrounding Ethereum is primarily focused on price volatility and technical chart setups, with traders debating whether the current market action represents a final accumulation zone or a prolonged downturn. Community sentiment remains mixed, as participants weigh institutional adoption and long-term network utility against ongoing price corrections and broader macroeconomic uncertainty.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDash is trending following the release of its latest earnings report, which triggered a significant price swing as investors reacted to the company's mixed results, marketplace volume data, and future outlook.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Discussion is fragmented as traders debate the project's long-term utility against its recent price performance. While some community members remain bullish, highlighting ongoing staking, product milestones, and potential regulatory clarity through the Clarity Act, others express frustration over stagnant price action and lack of mass adoption, with some labeling it a pump-and-dump scheme.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle shares are trending following the cancellation of a high-profile stock sale plan by Chairman Larry Ellison, with traders debating whether this signal of confidence will fuel a potential rebound despite ongoing concerns over heavy capital expenditure and cash flow pressures. Sentiment remains divided, as some investors view the company's strong earnings and backlog as a catalyst for growth, while others express skepticism regarding the company's AI-driven spending trajectory.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Abeona Therapeutics is trending as investors monitor the commercial rollout of ZEVASKYN and ongoing network expansion, with community discussion highlighting both the potential for significant revenue growth and the frustration surrounding the pace of patient treatments. While some traders emphasize the stock's fundamental undervaluation and long-term potential following recent treatment center activations, others express skepticism regarding management's execution and the timing of profitability.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO PR Newswire NEW YORK, Sept. 10, 2026 NEW YORK, Sept. 10, 2026...

ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abeona Therapeutics Inc. (Abeona or the Company) (NASDAQ: ABEO) for violations of the securities laws.INVESTIGATION DETAILS: The investigation...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO PR Newswire NEW YORK, Aug. 27, 2026 NEW YORK, Aug. 27, 2026 /PRNewswire...

Abeona Therapeutics Q2 2026 Earnings Call Transcript

Abeona Therapeutics (NASDAQ:ABEO) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call.
This content is powered by Benzinga APIs. For comprehensive financial dataread more...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Abeona Therapeutics Inc. (NASDAQ: ABEO)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Abeona Therapeutics Inc. (NASDAQ: ABEO) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Abeona Therapeutics Inc. (NASDAQ: ABEO) PR Newswire NEW YORK, July 27, 2026 NEW YORK, July 27...

Abeona Therapeutics Q1 2026 Earnings Call: Complete Transcript

Abeona Reports Strong Q1 Revenue, Expands Treatment Center Network

Abeona Therapeutics Inc. (NASDAQ: ABEO) reported first-quarter earnings Wednesday before the market opened. Here's a rundown of the report.read more...

Abeona Therapeutics (ABEO) to Release Quarterly Earnings on Wednesday

Abeona Therapeutics (NASDAQ:ABEO) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-13-abeona-therapeutics-inc-stock...

Abeona Therapeutics Inc. (NASDAQ:ABEO) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five brokerages that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the c...

2,000,000 Shares in Abeona Therapeutics Inc. $ABEO Purchased by AIGH Capital Management LLC

AIGH Capital Management LLC purchased a new position in Abeona Therapeutics Inc. (NASDAQ:ABEO - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 2,000,000 shares of the biopharmaceutical compa...

• Reported GAAP EPS of -$0.35 down -116.91% YoY
• Reported revenue of $11.38M up 2745.00% YoY

Abeona Therapeutics reported an increased quarterly net loss and revenue recognition challenges due to manufacturing yield issues, alongside structural risks concerning the complex production and shelf-life of ZEVASKYN therapy.

Abeona Therapeutics achieved steady ZEVASKYN launch growth and expanded its treatment center network, while securing CMS payment status to facilitate broader patient access and support long-term commercial adoption efforts.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Abeona Therapeutics’ Gene Therapy Gets FDA Nod For Treating Rare Genetic Skin Disease

Equity

Bearish Sentiment

President Trump has promised to issue a $5,000 "dividend" check to every adult American citizen if the Republican Party wins control of both the House and the Senate in the upcoming midterm elections, though the proposal would require congressional approval and follows his earlier $2,000 tariff-dividend plan, which stalled after the Supreme Court struck down much of his tariff authority. Do you think the $5,000 dividend check actually happens? Vote and explain your reasoning in the comments.

Trump has pledged a $5,000 &quot;dividend&quot; check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Stocktwits

Trump has pledged a $5,000 "dividend" check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Current Price	$5.42
Prev Close	$5.48
Open	$5.55
Dividend Yield	0.00%
50-Day Moving Average	$6.40
Beta	0.75
Avg. Volume	1.58M
PE Ratio	-4.82

52-Week High	$7.65
52-Week Low	$4.00
Market Capitalization	$309.65M
EPS (Annual)	$1.01
Price to Book	2.42
Revenue Per Employee	$25,752.21

Feed

News

Sentiment

Earnings

Fundamentals

Info

ABEO Fundamentals